In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Scientists have identified a gene that can help doctors predict which patients are likely to develop severe ulcerative colitis. The breakthrough, made by Danish researchers, means that for the first ...

A longer prednisolone tapering period is better than a shorter one at improving the rate of clinical remission in patients with moderate-to-severe ulcerative colitis.

VIENNA — Individuals with ulcerative colitis (UC) who carry the HLA-DRB1*01:03 allele are at increased risk of having a more severe disease course requiring major surgery, hospitalization, and ...

In a recent study published in the JAMA, a group of researchers identified biomarkers of severe ulcerative colitis through a Danish genome-wide association study (GWAS). Ulcerative colitis is a ...

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon driven by an abnormal immune response. It typically begins in the rectum and spreads continuously, occasionally involving a cecal ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

HLA-DRB1*01:03 allele linked to severe disease requiring hospitalization, major operation, systemic corticosteroid use. HealthDay News — For patients with ulcerative colitis, the HLA-DRB1*01:03 allele ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Although acute severe ulcerative colitis (ASUC) is recognized as a life-threatening flare associated with elevated thrombotic risk, the extent and duration of hypercoagulability after hospital ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...